Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
Overview
Paper Summary
This retrospective study found that treatment with hydroxychloroquine alone or in combination with azithromycin was associated with reduced mortality in hospitalized COVID-19 patients. Independent predictors of mortality included age, chronic kidney disease, and disease severity upon admission.
Explain Like I'm Five
In a large hospital study, COVID-19 patients treated with hydroxychloroquine, with or without azithromycin, seemed to have a better chance of survival. More research is needed to confirm this.
Possible Conflicts of Interest
One author disclosed receiving speaker's bureau honoraria from Bayer. Another author disclosed receiving similar honoraria from Gilead, ViiV, and Janssen. One author received consultation honoraria from ContraFect. All other authors declared no conflicts of interest.
Identified Limitations
Rating Explanation
Despite the large sample size, the retrospective and non-randomized design significantly limits the strength of the findings. The study's findings should be interpreted cautiously and validated by prospective randomized controlled trials before drawing firm conclusions.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →